Clinical Trials Browser

Observational × Recurrence × Brentuximab Vedotin × Clear all

NCT02139592 2020-07-13

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

292 enrolled 39 charts

Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03440788 2019-10-28

Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

Hodgkin Disease, Recurrence